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Abstract
Background: Prospective, observational studies that enroll large numbers of patients with few exclusion criteria
may better reflect actual ongoing clinical experience than randomized clinical trials. Our purpose was to obtain
efficacy and safety information from a cohort of subjects exposed to latanoprost/timolol fixed combination (FC) for
≥18 months using a prospective, observational design.
Methods: In all, 577 office-based ophthalmologists in Germany switched 2339 patients with glaucoma or ocular
hypertension to latanoprost/timolol FC for medical reasons. Follow-up visits were scheduled for every 6 months
over 24 months; physicians followed usual care routines. Intraocular pressure (IOP), visual field status, optic nerve
head findings, and adverse events were recorded. Efficacy parameters were evaluated for the per protocol (PP)
population; the safety population included subjects receiving ≥1 drop of FC. Physicians rated efficacy, tolerability,
and subject compliance at month 24.
Results: Of the 2339 subjects switched to latanoprost/timolol FC (safety population), the primary reasons for switching
were inadequate IOP reduction (78.2%) and desire to simplify treatment with once-daily dosing (29.4%; multiple reasons
possible). In all, 1317 (56.3%) subjects completed the study, and 1028 (44.0%) were included in the PP population. Most
discontinuations were due to loss to follow-up. Change in mean IOP from baseline to month 6 was -4.0 ± 4.31 mmHg,
a reduction that was maintained throughout (P < 0.05 for change at all time points). By investigator assessments, optic
disc parameters and visual field were stable over 24 months, and there was no relationship between IOP reduction over
24 months and development of a visual field defect. More than 90% of physicians rated latanoprost/timolol FC as “very
good” or “good” for efficacy (PP population), tolerability, and compliance. The FC was safe and well tolerated. No
change in iris color was reported by most subjects (83.1%) at month 24.
Conclusions: Over 24 months, latanoprost/timolol FC effectively lowers IOP levels and is well tolerated in patients with
glaucoma or ocular hypertension who change from their previous ocular hypotensive therapy for medical reasons.
Investigator assessments found optic disc parameters and visual field to be stable throughout 24 months of follow-up.
Background
In patients with glaucoma or ocular hypertension who
do not reach their target intraocular pressure (IOP)
level with ocular hypotensive monotherapy, the Eur-
opean Glaucoma Society [1] recommends adding a sec-
ond medication when the original agent showed some
effectiveness. In fact, many patients with these condi-
tions must use more than one ocular hypotensive ther-
apy to reduce IOPs to levels that may be expected to
slow or stop disease progression [2]. In these individuals,
a fixed-combination (FC) formulation may be preferred
to multidrug regimens in order to maximize patient
compliance and quality of life [1].
In Europe, the FC of the prostaglandin analogue lata-
noprost and the beta-blocker timolol is approved for the
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sion in patients insufficiently controlled on monother-
apy. Latanoprost, the first prostaglandin F2a analogue to
be commercially available in Europe and the United
States, acts primarily by increasing outflow [3,4] while
the beta-adrenergic receptor antagonist timolol lowers
IOP by reducing aqueous humor production [5,6]. The
combination of the two agents has been shown to have
an additive IOP-lowering effect [7-10], and several pro-
spective, randomized clinical trials have demonstrated
that latanoprost/timolol FC is effective and well toler-
ated [11-16].
Although such prospective, randomized trials are the
gold standard for evaluating the safety and efficacy of
new medical treatments, their strict designs may not
reflect community practice patterns thereby limiting the
generalizability of findings. Prospective, observational
studies that include large numbers of patients with few
exclusion criteria may better reflect actual ongoing clini-
cal experience. The present prospective, noninterven-
tional, observational study was designed to obtain
efficacy and tolerability information about a cohort of
subjects exposed to the latanoprost/timolol FC for at
least 18 months.
Methods
The study was conducted in general ophthalmology
practices in Germany between August 2005 and Decem-
ber 2008. The study met all standards for ethical
approval in Germany. It was planned and conducted
and data were analyzed in accordance with guidelines
issued by the Bundesinstitut für Arzneimittel und Medi-
zinprodukte (Federal Institute for Drugs and Medical
Devices). German law does not require patient informed
consent in observational studies in which treatment is
medically indicated by the physician regardless of study
participation and in which treatment use is restricted to
approved indications.
Procedures and measurements
In all, 577 office-based ophthalmologists treated and
provided information for 2339 subjects with glaucoma
or ocular hypertension who were being switched for
medical reasons to once-daily latanoprost/timolol FC
from another ocular hypotensive medication (monother-
apy, FC, or unfixed combination). Participating ophthal-
mologists followed their usual care practices. At the
baseline visit, the reason(s) for switching the subject to
latanoprost/timolol FC was noted, and demographic
data, medical and ocular histories, visual field status
(Aulhorn stage and mean defect), and optic nerve head
findings were recorded. Prior to pupil dilation, best-
corrected visual acuity was determined, and IOP level
was measured once by pulse air tonometry or calibrated
Goldman applanation tonometry.
Study-related follow-up visits were scheduled to occur
at approximately 6-month intervals for 24 months. At
each visit, IOP was measured, optic disc excavation and
visual field (Aulhorn stage) were assessed, and glaucoma
damage/progression was evaluated by investigators. Any
decision to withdraw FC therapy before 24 months was
made at the discretion of the treating physician.
All observed or volunteered adverse events and serious
adverse events were recorded throughout the study. Ser-
ious adverse events were those that were life-threaten-
ing, resulted in death, required or prolonged
hospitalization, or resulted in disability or congenital
anomaly. Suspected causal relationships to latanoprost/
timolol FC were recorded by treating physicians. Ver-
s i o n1 2 . 0o ft h eM e d i c a lD i c t i o n a r yf o rR e g u l a t o r y
Activities (MedDRA) was used to code diagnoses, pre-
vious/concomitant diseases, and adverse events.
Physicians assessed the overall efficacy and the overall
tolerability of latanoprost/timolol FC at month 24 as
“very good”, “good”, “moderate”,o r“insufficient”.S u b -
ject compliance with the FC was evaluated by physicians
using the same four categories. At month 24, subjects
evaluated change in iris color from baseline as “none”,
“slightly”, “distinctly”,o r“very distinctly” and were asked
whether they wished to remain on the FC.
Endpoints and analyses
Statistical analyses were descriptive and exploratory.
Percentages for categorical variables as well as means,
standard deviations (SDs), and, where appropriate, two-
sided 95% confidence intervals (CIs) for continuous vari-
ables were calculated based on nonmissing observations.
Associations between pairs of variables were assessed
using Pearson correlation for continuous variables,
Spearman rank correlation where one or both variables
were ordinal, or tetrachoric correlation for two binary
variables.
If both eyes were treated with the FC, the IOP value for
the right eye was used; otherwise, the value for the trea-
ted eye was used. If the physician did not indicate which
eye was treated, it was assumed that both eyes were pre-
scribed FC therapy. Mean changes in IOP levels at
months 6, 12, 18, and 24, and at the last visit were
assessed. In the analysis of changes in IOP, the last visit
was defined as the last postbaseline visit at which an IOP
level was recorded. In addition, mean change in corrected
IOP from baseline to last visit was assessed using the for-
mula developed by Kohlhaas et al. [17] (corrected IOP =
raw IOP + [-0.0423 × central corneal thickness in μm+
23.28]), and for the subset of subjects in whom IOP was
measured using applanation tonometry and for subjects
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therapy.
Mean changes from baseline in horizontal and vertical
cup/disc ratios were evaluated across visits. Aulhorn
stage and mean defect at each visit and change in stage
from baseline were summarized. A stepwise analysis of
variance (ANOVA) of mean change in visual field defect
(last visit at which the parameter was recorded - base-
line) included the following potential explanatory vari-
ables: age, gender, baseline mean defect, change in IOP
(last visit at which the parameter was recorded - base-
line), number of postbaseline optic disc hemorrhages,
treatment duration, primary diagnosis, history of hyper-
tension, history of hypotension, and history of diabetes.
The significance level for variable entry was set at 0.05
and for retention at 0.10; no interaction terms were
fitted.
A 6-item composite variable reflecting progression of
glaucomatous damage from baseline to last visit was
defined as any of the following: (a) increase in horizontal
or vertical cup/disc ratio by ≥0.2; (b) occurrence of ≥1
postbaseline optic disc hemorrhage; (c) decrease in rim
area, rim volume, and/or mean retinal nerve fiber layer
thickness by 0.2 mm
2,0 . 1m m
3 and 0.1 mm, respec-
tively, as measured by Heidelberg Retina Tomograph;
(d) progressive visual field deterioration noted by the
physician at ≥1 postbaseline visit; (e) increase in Aul-
horn stage by ≥1 stage; or (f) decrease in mean defect
by ≥2.5 dB. A stepwise logistic regression analysis of the
binary variable presence/absence of progression included
the following potential predictors: age, gender, baseline
IOP, change in IOP (last visit - baseline), primary diag-
nosis, history of hypertension, history of hypotension,
and history of diabetes. The significance level for vari-
able entry was set at 0.05 and for retention at 0.10; no
interaction terms were fitted. In addition, progression of
optic disc excavation (present if either criteria [a] or [c],
above, was met) and progression of visual field (present
if criteria [d] and if criteria [e] and/or [f] were met)
were evaluated.
Efficacy parameters were analyzed for the per protocol
(PP) population which included subjects treated with
latanoprost/timolol FC for ≥18 months who had a base-
line and ≥1 postbaseline IOP measurement (≥18 months
apart), did not have a refractive error ≤ -8 diopters or ≥
+ 8 diopters at baseline, and did not administer ocular
hypotensive medication in addition to latanoprost/timo-
lol FC medication during the study period. This defini-
tion of the PP population was appropriate given that the
primary objective of this noninterventional study was to
obtain information about a cohort of subjects exposed
to the latanoprost/timolol FC for at least 18 months. In
addition, key efficacy analyses were reproduced using
the full analysis set (FAS) population, which included all
subjects with ≥1 postbaseline IOP measurement, in
order to evaluate the robustness of the PP analyses. The
safety population included all subjects who received ≥1
drop of study medication.
Results
Of the 2339 subjects switched to latanoprost/timolol FC
(safety population), 1317 (56.3%) completed the study.
Subject disposition is summarized in Table 1. A total of
1022 subjects (43.7%) discontinued from the study; the
vast majority of discontinuations (894) were unrelated
to study drug, and nearly all of those (851) were attribu-
table to loss to follow-up. In all, 1028 subjects met
criteria for inclusion in the PP population, and 1934
were eligible for the FAS population.
In the total study population, the average age was 65.5
years, and 1047/2339 (44.8%) subjects were male (Table
2). The most common primary diagnoses were open-
angle glaucoma and ocular hypertension. The ocular
hypotensive therapies most often reported at the time of
the switch to the FC were latanoprost (n = 343), timolol
(n = 173), and timolol maleate (n = 115). (Investigators
could report the same drug as “timolol” or “timolol mal-
eate” reflecting different preferences in drug terms.) The
most commonly reported reasons for switching to the
FC were inadequate IOP reduction on prior therapy
(78.2%) and desire to simplify treatment with once-daily
dosing (29.4%; Table 2). The median duration of latano-
prost/timolol FC treatment was 708 days with 1491/
2339 (63.7%) subjects treated with the FC for at least
18 months.
In the PP population, the mean baseline IOP was
20.3 ± 4.20 mmHg (Table 3). A mean change from
baseline of -4.0 ± 4.31 mmHg was noted at month 6;
this decrease was maintained and reductions were statis-
tically significant throughout the follow-up period
(Table 3; Figure 1; P < 0.05 for each change from base-
line). Similar reductions from baseline to last visit were
noted when IOP values were corrected using the for-
mula proposed by Kohlhaas et al. [17]; in the FAS popu-
lation; and among the more than 600 subjects in the PP
population whose IOP levels were evaluated by applana-
tion tonometry (Table 4). With the PP population strati-
fied by primary diagnosis, mean ± SD changes from
baseline to last visit in IOP levels were -4.1 ± 4.34
mmHg in the open-angle glaucoma group (n = 859),
-4.6 ± 4.04 mmHg among those with ocular hyperten-
sion (n = 83), -5.1 ± 6.78 mmHg in pseudoexfoliation
glaucoma subjects (n = 48), and -3.2 ± 3.75 mmHg in
subjects with normal-tension glaucoma (n = 50). Strati-
fied by previous ocular hypotensive medication, mean
change in IOP from baseline to last visit was ≥-4.0
mmHg for those previously treated with a monotherapy
o rw i t has i n g l eF Ct h e r a p y ;t h em e a n±S DI O P
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from multiple therapies was -2.5 ± 4.48 mmHg (n =
119) and was -4.5 ± 4.77 mmHg in subjects for whom
the prior ocular hypotensive therapy was not recorded
(n = 586).
Changes from baseline in horizontal and vertical cup/
disc ratios showed a tendency toward stability and were
not considered to be clinically significant (Table 5).
Among subjects in the PP population for whom infor-
mation concerning whether or not they had an optic
disc hemorrhage at any postbaseline visit was available,
the percentage with a hemorrhage was lower at each fol-
low-up visit than at baseline (20/916 [2.2%] at baseline
vs ≤1.5% at any postbaseline visit). In all, 29/983 (3.0%)
reported ≥1 postbaseline optic disc hemorrhage, and 4/
983 (0.4%) had repeated occurrences at >1 postbaseline
visit.
Information concerning mean visual field defect mea-
surement method was available for 744 subjects, and the
most commonly used measurement method was the
Humphrey Visual Field Analyzer (n = 337). At month
24, 72 of the 122 subjects (59.0%) with valid data for the
A u l h o r ns t a g eb a s e do nt h eH u m p h r e yV i s u a lF i e l d
Analyzer at both baseline and month 24 had no change
in stage; 15.6%, 2.5% and 0.8% of subjects increased by
1, 2 and 3 stages, respectively, whereas 15.6%, 4.9%,
0.8% and 0.8% of subjects decreased by 1, 2, 3, and 4
stages, respectively.
In the PP population, there were no statistically signif-
icant changes in mean defect from baseline to months
6, 12, 18, and 24 or to the last visit. In the multivariate
analysis, change in mean defect from baseline to the last
visit was related only to baseline mean defect. This
analysis only involved subjects with nonmissing data for
the response variable and all potential explanatory vari-
ables (n = 355). The final model was reduced to a sim-
ple linear regression with intercept -0.718 and slope
-0.283 (95% CI: -0.354, -0.211; P < 0.0001). Hence, sub-
jects with a lower baseline mean defect experienced a
higher change in mean defect from baseline to last visit.
In addition, the correlation between changes from base-
line to last visit in mean defect and in IOP was esti-
mated at 0.0276 (95% CI: -0.0603, 0.1156; P = 0.5956;
n = 371), providing no evidence of a relationship
between IOP reduction and reduction in mean defect.
Fewer than 18% of evaluable subjects demonstrated a
negative change in any individual progression measure
by last visit or month 24 (Table 6). By the last visit, pro-
gression of optic disc excavation (increase in horizontal
or vertical cup/disc ratio by ≥0.2 or decrease in rim
area, rim volume, and/or mean retinal nerve fiber layer
thickness by 0.2 mm
2,0 . 1m m
3 and 0.1 mm, respec-
tively, as measured by Heidelberg Retina Tomograph)
was noted in 117/816 (14.3%) subjects. Visual field pro-
gression (progressive visual field deterioration noted by
the physician at ≥1 postbaseline visit and an increase in
Aulhorn stage by ≥1 stage and/or decrease in mean
defect by ≥2.5 dB) occurred in 46/900 (5.1%) of subjects
by the last visit. Based on the six-item composite vari-
able, overall progression of glaucoma by the last visit
was noted in 305 (30.2%) of the 1010 subjects in the PP
population who provided a response to ≥1o ft h es i x
individual progression measures. Logistic regression
demonstrated that only age was a significant predictor
of composite overall progression by the last visit (odds
ratio = 0.984; 95% CI: 0.972, 0.996; P = 0.0102;
Table 1 Subject disposition
No. (%) subjects
Received latanoprost/timolol FC 2339
Completed 24 months of follow-up 1317 (56.3)
Discontinued prior to 24 months 1022 (43.7)
Per protocol population
Included 1028 (44.0)
Excluded 1311 (66.0)
Reason(s) for exclusion:*
Not treated for ≥18 months 512
No baseline and ≥1 postbaseline measure for IOP ≥18 months apart 487
Additional ocular hypotensive medication during study 402
Ametropy at baseline 42
Full analysis set
Included 1934 (82.7)
Excluded (no postbaseline IOP measurement) 405 (17.3)
Safety population 2339 (100.0)
FC = fixed combination; IOP = intraocular pressure.
*More than one reason was possible. If a subject was excluded from the full analysis set, a separate reason for exclusion from the per protocol population is not
provided in this table.
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the probability of experiencing overall progression of
glaucoma damage increases with age.
Latanoprost/timolol FC was safe and well tolerated.
Sixteen deaths were reported, none of which was con-
sidered by investigators to be related to study treatment.
In all, 148 subjects treated with latanoprost/timolol FC
experienced 185 adverse events, and 88 treatment-
related adverse events were reported in 72 subjects
(Table 7). Three (0.1%) subjects experienced serious
adverse events deemed by investigators to be related to
study treatment. Fifty-two (2.2%) subjects permanently
discontinued treatment with the FC due to a treatment-
related adverse event. Ocular adverse events were the
most commonly reported adverse events. Treatment-
related ocular adverse events were noted in 39 (1.7%)
subjects, and 28 (1.2%) permanently discontinued FC
therapy due to such an event. Two (0.1%) subjects
experienced a serious treatment-related ocular adverse
event. Most adverse events resulting in discontinuation
were mild or moderate in severity and resolved by the
end of the study.
At month 24, the majority of responding physicians
rated the overall efficacy of latanoprost/timolol FC as
“very good” or “good” (PP population: 922/997 [92.5%];
FAS population: 1312/1504 [87.2%]). Among subjects
for whom physicians provided evaluations at month 24,
the overall tolerability of the FC was assessed as either
Table 2 Baseline characteristics, N = 2339
Age (years)*
Mean ± SD 65.5 ±
11.7
Range 10, 96
Male gender, n (%)* 1047
(44.8)
Primary diagnosis
†
Open-angle glaucoma 1910
Ocular hypertension 177
Pseudoexfoliation glaucoma 114
Normal-tension glaucoma 111
Glaucoma NOS 41
Angle-closure glaucoma 17
Pigmentary glaucoma 12
Ocular hypotensive therapy reported by ≥50 subjects
Bimatoprost 50
Brinzolamide 92
Dorzolamide/timolol FC 92
Latanoprost 343
Timolol 173
Timolol maleate 115
Travoprost 93
Reason(s) for switching to latanoprost/timolol FC,
‡ n (%)
Inadequate IOP reduction on prior therapy 1830
(78.2)
Desire to simplify treatment with once-daily dosing 687 (29.4)
Side effects/hypersensitivity reactions with prior therapy 219 (9.4)
Prior therapy contraindicated due to subject’s signs/
symptoms
103 (4.4)
Other 120 (5.1)
FC = fixed combination; IOP = intraocular pressure; NOS = not otherwise
specified; SD = standard deviation.
*Age was missing for 57 subjects; gender was missing for 48 subjects.
†Counts are based on diagnoses for both eyes. If a subject had a different
diagnosis for each eye, these were counted twice, and if a subject had more
than one diagnosis for the same eye, each was counted.
‡More than one reason could have been recorded by physicians. Percentages
are based on the number of patients (N = 2339).
Table 3 Mean IOP* and mean change in IOP from
baseline
† by visit (mmHg), PP population
Visit n Mean ± SD
(95% CI)
Change from baseline, mean ± SD
(95% CI
‡)
Baseline 1028 20.3 ± 4.20 n.a.
(20.1, 20.6)
Month 6 1012 16.4 ± 3.04 -4.0 ± 4.31
(16.2, 16.6) (-4.3, -3.8)
Month 12 1017 16.4 ± 3.04 -3.9 ± 4.53
(16.2, 16.6) (-4.2, -3.7)
Month 18 1010 16.4 ± 2.99 -4.0 ± 4.43
(16.2, 16.5) (-4.3, -3.7)
Month 24 980 16.2 ± 3.17 -4.2 ± 4.69
(16.0, 16.4) (-4.5, -3.9)
Last visit
§ 1028 16.2 ± 3.16 -4.1 ± 4.66
(16.0, 16.4) (-4.4, -3.8)
CI = confidence interval; IOP = intraocular pressure; n.a. = not applicable; PP =
per protocol;
SD = standard deviation.
*Raw IOP values.
†Month × - baseline.
‡P < 0.05 for change from baseline at each visit.
§Last visit = last postbaseline visit at which an IOP level was recorded.
Figure 1 Box-plot of intraocular pressure by visit, PP population.
PP = per protocol. Bars represent minimum and maximum values.
Boxes represent interquartile range and median. Line presents the
mean profile over time.
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compliance with the FC as “very good” or “good” in
1439/1580 (91.1%) subjects. More than three-quarters
(1123/1351 [83.1%) of responding subjects reported no
change in iris color at month 24, and nearly 90% (n =
1343/1520 [88.4%]) indicated a desire to continue FC
treatment after the completion of study. At month 24,
change in visual acuity from baseline was not statisti-
cally or clinically significant.
Discussion
Results of this long-term observational study of latano-
prost/timolol FC demonstrate that the combination
effectively reduces IOP levels and is well tolerated in
patients with glaucoma or ocular hypertension who
change from their previous ocular hypotensive therapy
for medical reasons. The significant IOP-lowering effect
of the FC was seen early, at the month 6 visit, and was
sustained throughout the 24-month follow-up period.
Moreover, no significant changes in optic disc and visual
field defect were noted by investigators, and structural
and functional parameters remained stable over 24
months. Investigator assessments revealed no significant
association between IOP reduction over two years and
change in visual field.
Previous research has demonstrated that progression
of glaucoma or ocular hypertension can be delayed or
halted by lowering IOP levels through the use of ocular
hypotensive agents [2,18-21]. Herein, the mean IOP
reduction of approximately 4 mmHg sustained over 24
months was somewhat greater than reductions reported
in previous short-term observational studies of patients
switched to the FC [22,23]. For example, a prospective,
multicenter study [22] of patients switched to latano-
prost/timolol FC and followed for at least two months
found mean IOP reductions from baseline of 2.9 mmHg
in those with primary open-angle glaucoma or exfolia-
tion glaucoma and of 3.1 mmHg among patients with
ocular hypertension (P < 0.001 for all). A multicenter,
observational study [23] of patients with glaucoma or
ocular hypertension who were switched to the FC and
followed for six months reported mean IOP reductions
from baseline of 3.3 mmHg, 4.1 mmHg, and 3.4 mmHg
among patients with open-angle glaucoma, exfoliation
glaucoma, and ocular hypertension, respectively (P <
0.001 for all).
As has been shown previously [11-16], the FC was
well tolerated. In all, 99/185 (53.5%) adverse events were
ocular in nature, half of treatment-related adverse events
related to the eye, and two of the three reported treat-
ment-related serious adverse events were ocular. Fewer
than 3% of subjects discontinued the FC due to an ocu-
lar adverse event. The tolerability of an ocular hypoten-
sive agent is important given the negative impact of
Table 4 Mean IOP and mean change in IOP from baseline
to last visit* (mmHg), alternate populations
Visit n Mean ± SD
(95% CI)
Change from baseline, mean ± SD
(95% CI
†)
PP population: corrected IOP[17]
Baseline 546 20.5 ± 3.94 n.a.
(20.2, 20.9)
Last visit 546 16.3 ± 3.30 -4.2 ± 4.21
(16.0, 16.6) (-4.6, -3.9)
Full analysis set: raw IOP
Baseline 1913 20.4 ± 4.25 n.a.
(20.2, 20.6)
Last visit 1934 16.4 ± 3.42 -3.9 ± 4.65
‡
(16.3, 16.6) (-4.2, -3.7)
PP population with applanation tonometry data: raw IOP
Baseline 732 20.3 ± 4.31 n.a.
(20.0, 20.6)
Last visit 687 16.2 ± 3.02 -4.0 ± 4.59
§
(16.0, 16.4) (-4.3, -3.6)
CI = confidence interval; IOP = intraocular pressure; n.a. = not applicable; PP =
per protocol;
SD = standard deviation.
*Last visit = last postbaseline visit at which an IOP level was recorded.
†P < 0.05 for change from baseline to last visit for each parameter.
‡N = 1913.
§N = 631.
Table 5 Mean change from baseline* in horizontal and
vertical cup/disc ratios by visit, PP population
Visit n Mean ± SD (95% CI)
Horizontal cup/disc ratio
Month 6 645 0.0003 ± 0.13117
(-0.0099, 0.0104)
Month 12 660 0.0039 ± 0.13286
(-0.0063, 0.0140)
Month 18 666 0.0092 ± 0.13860
(-0.0014, 0.0197)
Month 24 666 0.0041 ± 0.14078
(-0.0067, 0.0148)
Last visit 783 0.0079 ± 0.14645
(-0.0024, 0.0182)
Vertical cup/disc ratio
Month 6 600 0.0040 ± 0.12772
(-0.0062, 0.0142)
Month 12 604 0.0075 ± 0.13726
(-0.0035, 0.0184)
Month 18 613 0.0152 ± 0.14613
(0.0036, 0.0268)
Month 24 615 0.0088 ± 0.13534
(-0.0019, 0.0195)
Last visit 729 0.0127 ± 0.15155
(0.0017, 0.0237)
CI = confidence interval; PP = per protocol; SD = standard deviation.
*Month × - baseline. Last visit = last postbaseline visit at which the parameter
was recorded
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apy [24,25].
At month 24, physician evaluations of latanoprost/
timolol FC were overwhelmingly positive with regard to
efficacy, tolerability, and patient compliance. In addition,
nearly 90% of patients expressed a desire to remain on
the FC after the end of the study. These positive evalua-
tions are tempered, however, by the fact that they were
made for and by patients who stayed on therapy for the
full follow-up period; it is not known how many of
those for whom efficacy, tolerability, or compliance were
issues discontinued FC therapy prior to that time point.
Conversely, nearly 90% of discontinuations in the pre-
sent study were unrelated to latanoprost/timolol FC,
with the vast majority attributable to loss to follow-up.
Moreover, a prior study [23] of patients switched to
latanoprost/timolol FC found that 97% of patients
(1008/1042) remained on treatment after the 6-month
study period.
Benefits of prescribing a FC agent for patients with
glaucoma or ocular hypertension may include improved
adherence, persistence, convenience, and reduced expo-
sure to preservatives. Improved adherence and persis-
tence, in particular, are critical since the use of an
effective ocular hypotensive agent over the long term
may be expected to increase the likelihood of delaying
or stopping glaucomatous damage. Poorer compliance
has been demonstrated in those treated with more com-
plex medication regimens [26-30]. Comparative studies
of medication compliance in patients prescribed alterna-
tive FC therapies are needed.
This study has both strengths and limitations. The
observational design may have better reflected actual
clinical practice than controlled clinical trials, but the
absence of a control group limits our ability to draw
conclusions, and the PP population included fewer than
half the number of subjects treated, primarily due to
loss to follow-up. Given the observational design, it was
Table 6 Changes in progression measures by last visit* and month 24, n/N (%), PP population
Progression measure Last visit Month 24
Increase in horizontal or vertical cup/disc ratio by ≥0.2 (visit - baseline)
† 98/797 (12.3) 78/676 (11.5)
≥1 postbaseline optic disc hemorrhage
‡ 29/983 (3.0) 23/785 (2.9)
Decrease in ≥1 rim area, rim volume, and/or mean RNFL thickness by HRT (visit - baseline)
† 28/222 (12.6) 13/151 (8.6)
Visual field deterioration rated as progression by physician at ≥1 postbaseline visit
‡ 137/884 (15.5) 104/630 (16.5)
Increase in Aulhorn stage
§ by ≥1 stage (visit - baseline)
† 64/370 (17.3) 43/258 (16.7)
Decrease in mean defect by ≥2.5 dB
† 59/371 (15.9) 45/285 (15.8)
HRT = Heidelberg Retina Tomograph; PP = per protocol; RNFL = retinal nerve fiber layer.
*Last visit = last postbaseline visit at which the parameter was recorded.
†To be included in the percentage, a subject must have had assessments at both the baseline and ≥1 postbaseline visit for the relevant measure.
‡To be included in the percentage, a subject must have had ≥1 postbaseline assessment for the relevant measure.
§Reflects all methods of determining Aulhorn stage.
Table 7 Adverse events, N = 2339
All causalities
n (%)
Treatment related
n (%)
All adverse events
Number of events 185 88
Subjects with:
≥1 adverse event 148 (6.3) 72 (3.1)
≥1 serious adverse event 54 (2.3) 3 (0.1)
≥1 severe adverse event 70 (3.0) 15 (0.6)
Discontinued FC due to adverse event 69 (2.9) 52 (2.2)
Dose reduced/temporarily discontinued FC due to adverse event 22 (0.9) 8 (0.3)
All Ocular Adverse Events
Number of events 99 44
Subjects with:
≥1 adverse event 84 (3.6) 39 (1.7)
≥1 serious adverse event 29 (1.2) 2 (0.1)
≥1 severe adverse event 35 (1.5) 5 (0.2)
Discontinued FC due to adverse event 41 (1.8) 28 (1.2)
Dose reduced/temporarily discontinued FC due to adverse event 19 (0.8) 6 (0.3)
FC = fixed combination.
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Page 7 of 9not possible to standardized the timing and method of
measuring IOP levels and visual field defects. It is nota-
ble, however, that IOP reductions from baseline to last
visit among the 687 subjects evaluated by applanation
tonometry were similar to those observed for the total
population. Although the design did not include a wash-
out period between termination of baseline therapy and
initiation of latanoprost/timolol FC combination, this
would not be expected to impact the long-term out-
comes evaluated herein. The 24-month follow-up period
may have been too short to detect changes in visual
fields. Moreover, last visit data for individual progression
measures reflected a time point prior to month 24 for
between 15% (for cup/disc ratio data) and 32% (for rim
area/volume/retinal nerve fiber layer data) of evaluable
subjects. Strict adherence to study procedures and
reporting requirements could not be affirmed given the
large number of participating physicians and the pro-
longed follow-up period. Finally, while 17% of patients
reported a change in iris color from baseline to month
24, evaluations relied on recollections of baseline color.
The Ocular Hypertension Treatment Study [2] found
that 17.1% of subjects prescribed a prostaglandin analo-
gue for at least six months and 7.6% of those in the
observation group reported a change in iris color, dar-
kening of the eyelids, or growth of eyelashes.
Conclusions
This 24-month study demonstrated that latanoprost/
timolol FC effectively reduces IOP levels and is well tol-
erated in patients switched from other ocular hypoten-
sive therapies for medical reasons. Investigator
assessments showed optic disc parameters and visual
field to be stable throughout the follow-up period.
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